Summary Twenty-four symptomatic patients with advanced non-small cell lung cancer (NSCLC) were treated with cisplatin-based chemotherapy (mitomycin-C 8 mg m 2q 6 weeks, vinblastine 6 mg m2q 3 weeks, cisplatin 50 mg m-2q 3 weeks). Patients were assessed for symptom relief as well as for objective response.
Until recently there was little evidence to suggest that chemotherapy was of any real clinical benefit for patients with advanced non-small cell lung carcinoma (Elliot, 1986; Bakowski & Crouch, 1983) . The development of cisplatincontaining combinations was associated with a trend towards higher response rates than those previously reported, but these were still restricted to 30-40% with few complete remissions (Gralla et al., 1981; Hoffman et al., 1983; Sculier & Klatersky, 1984) . Furthermore, treatment with cisplatin, particularly at doses of around 100 mg m-2, was associated with unpleasant toxicity and there were few convincing reports of good symptom control or improved quality of life. In addition, first reports from randomised trials suggested no significant survival advantage with chemotherapy (Lad et al., 1981; Laing et al., 1975) . Against this background, it is hardly surprising that a Canadian study found that more than 80% of doctors questioned would not wish chemotherapy if they had metastatic non-small cell lung cancer (MacKillop et al., 1987) .
Recently, the picture has begun to look a little more optimistic. An update of an earlier trial (Williams et al., 1988) has shown a trend towards improved survival, and several new trials have shown a small but significant survival benefit for patients receiving chemotherapy compared to control groups receiving symptomatic management alone (Cormier et al., 1982; Rapp et al., 1988) . Moreover, there have been reports of chemotherapy leading to significant palliation and improvement in overall quality of life in patients with NSCLC (Cullen et al., 1988; Folman & Rosman, 1988) . The combination of mitomycin-C, vinblastine and cisplatin is one of many cisplatin combinations to have shown activity against non-small cell lung carcinoma (Folman & Rosman, 1988; Giaccone et al., 1987; Gralla & Kris, 1988 and the dose of cisplatin decreased accordingly as follows: EDTA>80 ml min-., full dose; EDTA 60-80 ml min-', 25% dose reduction; EDTA 40-60 ml min-', 50% dose reduction; EDTA <40 ml min-', no cisplatin. Treatment was continued until progression of disease, fall in performance status, or to a maximum of six cycles.
Assessment of response and toxicity Patients were assessed before treatment with physical examination, routine haematology and biochemistry, chest X-ray and other radiological examinations as indicated. Patients were reviewed at day 10 following the first treatment course and before each treatment cycle thereafter for assessment of response and toxicity according to standard WHO criteria (Miller et al., 1981) . Duration of response was measured from the date of first treatment.
Assessment ofsymptomatic response Symptoms were recorded at the start of treatment under the general headings malaise, pain, cough, dyspnoea and 'other' (which was then specified). Symptoms were reassessed 3 weeks after each course of chemotherapy with patients asked to grade change in symptoms using simple descriptive criteria as follows: (i) much better (MB), complete disap-pearance of symptoms; (ii) better (B), good improvement of symptoms; (iii) no change (NC), minor or no improvement in symptoms; (iv) (Table I ). This included complete disappearance of at least one symptom in five patients (21%). Response for specific symptoms were as follows: malaise 4/8 patients (50%), pain 10/16 patients (63%), cough 10/14 patients (71%) and dyspnoea 11/17 patients (65%). Relief of at least one symptom according to number of symptoms per patient was as follows: one symptom, 2/2 patients; two symptoms, 5/8 patients; three symptoms, 9/11 patients; four or more symptoms 2/3 patients.
The overall symptomatic response rate was 67%, with 16 of 24 patients feeling better or much better at some stage during treatment.
All five patients achieving an objective partial remission also experienced symptomatic relief (Table I) .
The median duration of symptomatic response was shortlived, at 7 weeks (range 4-32 weeks).
The median number of treatment courses given was three (range one to six). Five patients completed six courses of treatment with no fall in performance status. The remaining 19 patients discontinued treatment before six courses because of progressive disease, lack of response or deteriorating general condition.
Eight of 19 patients (42%) lost more than 2 kg in weight while on treatment.
Toxicity
In general toxicity was mild (see Table II 
Discussion
The most striking clinical feature of this study was the high incidence of symptomatic relief (75%) despite the low objective response rate of only 21%. This symptomatic relief was achieved without serious morbidity and in the total absence of significant alopecia. For most patients, however, the benefit was short-lived, with a median duration of only 7 weeks.
One obvious explanation for the discrepancy between symptomatic and objective response is that the tratment was simply having a placebo effect. The short duration of improvement for many patients might support this. However, we were impressed by the quality of symptomatic improvement, and an alternative explanation, such as a local biochemical effect on the tumour, cannot be completely excluded.
The study has implications for future trials of chemotherapy in advanced non-small cell lung cancer. A higher dose schedule might have achieved a higher response rate, as suggested by other groups using this combination 
